Is Bristol Myers Squibb (BMY) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 04/22/21
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma.Business Wire • 04/16/21
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell CarcinomaBusiness Wire • 04/14/21
Why This Bristol-Myers Squibb Stock Analyst Is Turning Bullish On The Pharma Company's PipelineBenzinga • 04/13/21
Buy Bristol Myers, Analyst Says. It Isn't Getting Enough Credit for Its Drug Pipeline.Barrons • 04/13/21
Rose 95 Stock Portfolio March Madness Q1 Update Including Cost/Share And Purchase Evaluation ListSeeking Alpha • 04/13/21
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 TrialBusiness Wire • 04/10/21
Is Bristol Myers Stock A Buy As Opdivo Faces An FDA Hurdle In April?Investors Business Daily • 04/09/21
CORRECTING and REPLACING Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal.Business Wire • 04/08/21
Bristol-Myers' Opdivo-Chemo Combo Associated With Overall Survival Benefit In Esophageal CancerBenzinga • 04/08/21
Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell CarcinomaBusiness Wire • 04/08/21
PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology CollaborationBusiness Wire • 04/07/21